<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 18 May 2021 07:29:49 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>多肽类药物发展历程与市场简述</title><link>https://mp.weixin.qq.com/s/OXMWwnYMuJfXPFw9N6JC2w</link><description></description><content:encoded><![CDATA[多肽类药物发展历程与市场简述]]></content:encoded><pubDate>Tue, 18 May 2021 06:32:53 +0800</pubDate></item><item><title>康方生物：一群成功的科学家</title><link>https://mp.weixin.qq.com/s/F9WrtAET4XRl1QBdFJfcng</link><description></description><content:encoded><![CDATA[康方生物：一群成功的科学家]]></content:encoded><pubDate>Mon, 17 May 2021 06:57:42 +0800</pubDate></item><item><title>双抗，下一代抗体药物</title><link>https://mp.weixin.qq.com/s/PXxmlLWmjdqEpARFHW3qtA</link><description></description><content:encoded><![CDATA[双抗，下一代抗体药物]]></content:encoded><pubDate>Sun, 16 May 2021 08:05:02 +0800</pubDate></item><item><title>群雄逐鹿，东海论药｜BiG七周年大咖云集</title><link>https://mp.weixin.qq.com/s/JMDUYkaOyGA_jfwgs4aLjw</link><description></description><content:encoded><![CDATA[群雄逐鹿，东海论药｜BiG七周年大咖云集]]></content:encoded><pubDate>Sat, 15 May 2021 06:40:03 +0800</pubDate></item><item><title>免疫检查点与自身免疫性疾病</title><link>https://mp.weixin.qq.com/s/w1SspVQc_xNVbPrSwBlYZg</link><description></description><content:encoded><![CDATA[免疫检查点与自身免疫性疾病]]></content:encoded><pubDate>Sat, 15 May 2021 06:40:03 +0800</pubDate></item><item><title>TROP-2 ADC药物临床实验总览</title><link>https://mp.weixin.qq.com/s/xGm0cYlqgrJvRvjKA1qL-Q</link><description></description><content:encoded><![CDATA[TROP-2 ADC药物临床实验总览]]></content:encoded><pubDate>Fri, 14 May 2021 06:46:11 +0800</pubDate></item><item><title>贝达药业、倍而达药业、三代EGFR-TKI，三者之间的爱恨情仇</title><link>https://mp.weixin.qq.com/s/f8NdjAU3TGLo3jiu_HGcng</link><description></description><content:encoded><![CDATA[贝达药业、倍而达药业、三代EGFR-TKI，三者之间的爱恨情仇]]></content:encoded><pubDate>Thu, 13 May 2021 07:50:26 +0800</pubDate></item><item><title>2021 ASCO GU 免疫治疗新进展-尿路上皮癌（上）</title><link>https://mp.weixin.qq.com/s/xhV1P9xBKfhNyjUj2gWf-A</link><description></description><content:encoded><![CDATA[2021 ASCO GU 免疫治疗新进展-尿路上皮癌（上）]]></content:encoded><pubDate>Wed, 12 May 2021 18:26:33 +0800</pubDate></item><item><title>2021 ASCO GU 免疫治疗新进展-尿路上皮癌（下）</title><link>https://mp.weixin.qq.com/s/DKyyKad55BzoGEy0Xaw1Vw</link><description></description><content:encoded><![CDATA[2021 ASCO GU 免疫治疗新进展-尿路上皮癌（下）]]></content:encoded><pubDate>Wed, 12 May 2021 18:26:33 +0800</pubDate></item><item><title>调节性T细胞治疗的未来：CAR-Treg</title><link>https://mp.weixin.qq.com/s/sd_QCapRbrBYDnN8G-huEA</link><description></description><content:encoded><![CDATA[调节性T细胞治疗的未来：CAR-Treg]]></content:encoded><pubDate>Tue, 11 May 2021 07:15:19 +0800</pubDate></item><item><title>信达生物管线格局：成长中的Pharma</title><link>https://mp.weixin.qq.com/s/8MTCTVfND4YEEJxoTAw3Kw</link><description></description><content:encoded><![CDATA[信达生物管线格局：成长中的Pharma]]></content:encoded><pubDate>Mon, 10 May 2021 06:26:27 +0800</pubDate></item><item><title>盘点！抗癌药物飞速发展的五年</title><link>https://mp.weixin.qq.com/s/y5v5ul5T7olG3-9R21_tgw</link><description></description><content:encoded><![CDATA[盘点！抗癌药物飞速发展的五年]]></content:encoded><pubDate>Sun, 09 May 2021 07:21:05 +0800</pubDate></item></channel></rss>